Comparison
NMN vs Urolithin A (Mitopure)
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Urolithin A (Mitopure)
Bioactive metabolite of pomegranate ellagitannins. Direct mitophagy activator. The supplement form bypasses the gut microbiome variability.
| Field | NMN | Urolithin A (Mitopure) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 500–1000mg |
| Half-life | — | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 280 |
The comparison in plain English
Auto-generated from dataNMN and Urolithin A (Mitopure) are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Urolithin A (Mitopure) Bioactive metabolite of pomegranate ellagitannins.
Bottom line
NMN (evidence B, safety 5/5) matches the evidence base of Urolithin A (Mitopure) (evidence B, safety 5/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Urolithin A (Mitopure) if
Urolithin A (Mitopure) is the better fit when your goal aligns with its mechanism (Selectively activates mitophagy — the autophagy of damaged mitochondria — through PINK1/Parkin signaling) and the dose range (500–1000mg) suits your protocol. Half-life is —h.